(in millions, except per share data and additional information)
2017
2016
2015 (1)
2014
2013
Operating Results:
Net sales
$
29,710
$
28,833
$
20,261
$
17,005
$
16,590
Cost of products sold
9,291
9,142
6,309
4,333
4,126
Research and development expense
2,193
2,224
1,640
1,477
1,557
Selling, general, and administrative expense
9,711
9,469
6,904
5,847
5,698
Special charge (gain), net
100
70
(38
)
40
—
Restructuring charges, net
363
290
237
78
172
Certain litigation charges
300
26
42
770
245
Acquisition-related items
220
283
550
117
(49
)
Amortization of intangible assets
1,980
1,931
733
349
331
Other expense, net
222
107
118
181
108
Operating profit
5,330
5,291
3,766
3,813
4,402
Operating profit margin percent
17.9
%
18.4
%
18.6
%
22.4
%
26.5
%
Interest expense, net
728
955
280
108
151
Income before provision for income taxes
4,602
4,336
3,486
3,705
4,251
Provision for income taxes
578
798
811
640
784
Net income
4,024
3,538
2,675
3,065
3,467
Net loss attributable to noncontrolling interests
4
—
—
—
—
Net income attributable to Medtronic
$
4,028
$
3,538
$
2,675
$
3,065
$
3,467
Per Ordinary Share:
Basic - Net income attributable to Medtronic
$
2.92
$
2.51
$
2.44
$
3.06
$
3.40
Diluted - Net income attributable to Medtronic
2.89
2.48
2.41
3.02
3.37
Cash dividends declared per ordinary share
1.72
1.52
1.22
1.12
1.04
Financial Position at Fiscal Year-end:
Working capital
$
10,316
$
16,435
$
21,671
$
15,651
$
13,902
Current ratio (2)
1.7:1.0
3.3:1.0
3.4:1.0
3.8:1.0
4.5:1.0
Total assets
99,816
99,644
106,685
37,943
34,900
Long-term debt
25,921
30,109
33,752
10,315
9,741
Shareholders’ equity
50,294
52,063
53,230
19,443
18,671
Additional Information:
Full-time employees at year-end
91,267
88,063
85,573
43,305
42,466
Full-time equivalent employees at year-end
102,688
98,017
92,500
49,247
46,659
(1)
Covidien was acquired on January 26, 2015. As such, for the fiscal year ended April 24, 2015, the results of operations of Covidien are reflected in Medtronic’s results of operations for only the fourth quarter due to the timing of the acquisition, which affects comparability.
(2)
The ratio of current assets to current liabilities, excluding current assets and current liabilities held for sale at April 28, 2017.